GlassScriptPhysician profile
Sohail Kareem
NPI 1396760112
$5,667.61
in general payments reported to CMS, 2019-2025
31 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $573 · 2021: $631 · 2022: $816 · 2023: $1,040 · 2024: $1,169 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $677.41 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $570.28 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $564.74 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $502.67 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $415.12 | 2021-2025 | |
| Vifor Pharma, INC. | $357.41 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $344.19 | 2019-2025 | Jynarque |
| Amgen INC. | $275.73 | 2019-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $249.96 | 2020-2025 | Benlysta, Shingrix |
| Aurinia Pharma U.S., INC. | $233.41 | 2021-2024 | Lupkynis |
| Daiichi Sankyo INC. | $164.20 | 2019-2022 | |
| Horizon Therapeutics Plc | $156.08 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $142.34 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $138.80 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $120.75 | 2020-2024 | Terlivaz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $92.33 | 2021-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.91 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $81.68 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $64.40 | 2024 | Velphoro |
| Ardelyx, INC. | $63.70 | 2024 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $57.34 | 2020 | |
| Akebia Therapeutics INC | $52.53 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $51.00 | 2019-2024 | Ultomiris |
| Cormedix INC. | $43.45 | 2024-2025 | Defencath, Defencath |
| Mallinckrodt Enterprises LLC | $37.64 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $32.76 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.42 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.96 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.43 | 2019 | |
| Genentech USA, INC. | $16.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Kareem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.